Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of <sup>18</sup>F-DCFPyL PET/CT with Comparison to Multiparametric MRI

Background Prostate cancer recurrence is found in up to 40% of men with prior definitive (total prostatectomy or whole-prostate radiation) treatment. Prostate-specific membrane antigen PET agents such as 2-(3-{1-carboxy-5-[(6-[18F]fluoro-pyridine 3-carbonyl)-amino]-pentyl}-ureido)-pentanedioic acid...

Ful tanımlama

Kaydedildi:

Detaylı Bibliyografya
Asıl Yazarlar:	Liza Lindenberg, Esther Mena, Barış Türkbey, Joanna H. Shih, Sarah E. Reese, Stephanie A. Harmon, Ilhan Lim, Frank I. Lin, Anita Ton, Yolanda McKinney, Philip Eclarinal, Deborah E. Citrin, William L. Dahut, Ravi A. Madan, Bradford J. Wood, Venkatesh Krishnasamy, Richard Chang, Elliot Levy, Peter A. Pinto, Janet F. Eary, Peter L. Choyke
Materyal Türü:	Artigo
Dil:	İngilizce
Baskı/Yayın Bilgisi:	2020
Online Erişim:	https://doi.org/10.1148/radiol.2020192018
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!

İlk yorumlayan siz olun!

Evaluating Biochemically Recurrent Prostate Cancer: Histologic Validation of <sup>18</sup>F-DCFPyL PET/CT with Comparison to Multiparametric MRI

Benzer Materyaller